Company Analysis

Telomir Pharmaceuticals, Inc. (TELO)

Nasdaq: TELO · Pharmaceutical Preparations · Miami, FL · filing with the SEC since 2023
Grade4.5
◀ Past 5.2● Present 3.6▶ Future 5.0
7 est.

Who runs Telomir Pharmaceuticals, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Aminov Erez
CEO and Chairman. First filing Aug 2024, latest May 22, 2026, 0 filings in all.
Officers reporting now
2
of 5 people with a filing in the last fifteen months
Directors reporting now
3
15 people on the record since 2024
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Mushak AndriyChief Financial OfficerJun 2026Jun 9, 2026none
Aminov ErezCEO and ChairmanAug 2024May 22, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Del Giudice Matthew PauldirectorAug 2024Jul 27, 2026none
Macpherson Edward CloustondirectorAug 2024Jul 27, 2026none
Whalen Matthew PrattdirectorAug 2024Jul 27, 2026none
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Mira Pharmaceuticals, Inc.10% ownerOct 2025Oct 3, 2025none
Earlier names on the record12, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton TELO · research, not advice